Kromann Reumert assists Teitur Trophics in connection with their EUR 28 million Series A financing to advance
Teitur Trophics, a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases, has completed an EUR 28 million Series A financing.
The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from Industrifonden, Innovestor’s Life Science Fund and P53 Invest. The proceeds will enable Teitur to progress its lead drug candidate, TT-P34, from candidate selection into clinical development, including a Phase 1b clinical study in neurodegenerative diseases.
Teitur is a spin out from Aarhus University and was seeded by the BioInnovation Institute in 2020.
We have assisted Teitur Trophics in the financing.
Read more: Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases – Teiturtrophics (teiturtrophics.com)
Contact
